Article Text

Download PDFPDF

4CPS-151 Influence of the route and pharmaceutical preparation in intra-patient variability of tacrolimus serum levels in the liver transplant patient
  1. S Garcia Garcia1,
  2. C Dopazo Taboada2,
  3. MB Aller Hernández3,
  4. I Bilbao Aguirre2,
  5. E Pericas Bosch3,
  6. JB Montoro Ronsano1
  1. 1Vall d’Hebron Hospital, Pharmacy Service, Barcelona, Spain
  2. 2Vall d’Hebron Hospital, Hepatolobiliar Surgery Service, Barcelona, Spain
  3. 3Vall d’Hebron Hospital, Artificial Intelligence Information Service, Barcelona, Spain


Background In the earliest stages, immunosuppressive therapy in liver transplant patients (LTP) is targeted to avoid acute rejection, to preserve graft survival and to minimise the risk of pharmacological adverse reactions. The use of different administration routes or immediate-prolonged release preparations could influence tacrolimus serum levels (FKs) and variability.

Purpose To assess the mean concentration and the intra-patient variability (IPV) of FKs after their administration through immediate-prolonged release preparations and/or different administration routes in LTP.

Material and methods Observational retrospective study including LTP within 2015–2017.

Clinical data was collected from the hospital’s medical records, including: type of transplant, date of surgery, tacrolimus pharmaceutical form (TacPP), administration route and FKs values within 1 month after liver transplant.

FKs mean levels, coefficient of variation (CV), proportion of patients with CV >30% (CV30) and proportion of FKs values lower than 5 ng/mL (P5) per patient were calculated. The influence of the TacPP administered (immediate/prolonged/extended release) and the administration route (oral/nasogastric tube), in case of immediate-release tacrolimus form was also analysed.

Therapeutic control was considered inadequate if CV30 occurred, or P5 was higher than 20%.

Statistical analysis was done using SPSS. Variance analysis and the Krukal–Wallis test were used to compare quantitative variables.

Results Eighty-four patients were included. The values of the variables analysed – mean FKs, P5 and CV30 observed – were 8.0 ng/mL (SD, 4.2), 19.3% (SD, 39.6) and 66.0% (DE, 46.9). Technically, 68.3% patients had poor FKs control levels.

According to TacPP, values for mean FKs, P5 and CV30 observed were:

Immediate-release tacrolimus: 8.5 ng/mL (95% CI: 6.2 to 10.9), 28.6% (–95% CI: 12.8 to 44.3) and 58.1% (95% CI: 39.7 to 76.5).

Prolonged-release tacrolimus: 7.9 ng/mL (95% CI: 6.2 to 10.9), 10.5% (95% CI: 1.0 to 25.6) and 66.7% (95% CI: 55.0 to 78.3).

Extended-release tacrolimus: 9.6 ng/mL (95% CI: 8.0 to 11.3), 8.3% (95% CI: 0.0 to 27.0) and 83.3% (95% CI: 58.6 to 100.0).

According to the administration route (immediate-release tacrolimus form), values for mean FKs, P5 and CV30 observed were:

Oral: 8.5 ng/mL (95% CI: 6.2 to 10.9), 28.6% (95% CI: 6.7 to 24.9) and 58.1% (95% CI: 40.0 to 76.5).

Nasogastric tube: 6.8 ng/mL (95% CI: 5.5 to 8.0), 32.3% (95% CI: 14.8 to 49.7) and 76.0% (95% CI: 58.0 to 94.0).

Mean FKs, P5 and CV30 observed varied widely among the TacPP and administration route: statistical differences were only achieved for P5 within TacPP (p=0.044).

Conclusion Taking into account the limitations of this study, our findings suggest that high IPV of FKs exist, at least within the first month after the transplant date. Moreover, the IPV of FKs after their administration through immediate-prolonged release preparations and/or a different administration route shows a wide range of variability that in concrete cases (P5) raises statistical significance.

References and/or acknowledgements Thanks to all authors for their involvement.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.